Breaking News

The company is offering units consisting of preferred stock and warrants to purchase shares of its common stock.

Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.

Third quarter sales of $535.0 million beat analysts' average estimate of $508 million and represented 3 percent growth on a currency-neutral basis.

GenMark placed 65 ePlex analyzers in Q3, the first full quarter after the platform's launch in the US, and it expects to exit 2017 with up to 200 placements.

The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.

The company beat analyst estimates on the top and bottom lines, and said sales from its diagnostics business rose 13 percent year over year.

The company posted revenues of $435.6 million, up from $393.9 million in Q3 2016, beating the consensus Wall Street estimate of $414.6 million.

The company's product revenues increased over the prior year period, although total revenues missed analysts' average forecast. 

Examining five types of bacterial environments in patients' stomachs, researchers found that non-Helicobacter pylori microbiota may lead to gastric cancer development.

A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.

Batang Toru orangutan

Using genome sequencing, phylogenomics, morphological analyses, and more, investigators defined a rare new orangutan species dubbed Pongo tapanuliensis.

The company will use the funds to increase its overseas footprint, and to optimize its genetic testing procedures and protocols, among other improvements.

Syngenta said that it is using CRISPR-Cas9 in multiple crops including corn, wheat, tomato, rice, and sunflower.

The results reflected the divesture of the firm's respiratory solutions business. The firm beat the consensus Wall Street estimates on the top and bottom lines. 

Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.

Washington University will partner with CureOne to link its NGS-based cancer tests with the N1 Registry, where patients can find treatment and outcomes data.

The tuberculosis and antibiotic-resistance test had been marketed in India by Xcelris Labs under a 2012 agreement.

The company beat analyst estimates on both the top and bottom line and reported a 50 percent year over year growth in clinical testing volume in Q3.

The firm's molecular business also continued to grow, with a revenue increase of 13 percent.

The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.

Expression and copy number profiles from histologically normal duct tissue near tumors suggest a "field of cancerization" may exist in epithelial cells around cancer.

Researchers crowdsourced thousands of microbiome samples to examine global microbial diversity and generate a resource for researchers.

The company said it would use the proceeds to continue the expansion of its sales force and bring new skin cancer products to market in 2018.

The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.

Pages

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.